A Phase-II, Randomised, Double-blind, Parallel-group, Proof-of-concept Trial to Investigate ABBV-4083 Given for 7 or 14 Days or in Combination With Albendazole in Subjects With Onchocerca Volvulus Infection, Comprising: Part 1 to Investigate Safety, Tolerability, Efficacy for Dose-Ranging and Pharmacokinetics; Part 2 to Investigate Efficacy of Selected Doses, Safety, Tolerability and Pharmacokinetics
Latest Information Update: 26 Sep 2023
At a glance
- Drugs Albendazole (Primary) ; Flubentylosin (Primary) ; Ivermectin (Primary)
- Indications Onchocerciasis
- Focus Proof of concept; Therapeutic Use
- Sponsors AbbVie
- 19 Sep 2023 Status changed from recruiting to discontinued.
- 03 Feb 2023 Planned End Date changed from 17 Jan 2025 to 19 Dec 2025.
- 03 Feb 2023 Planned primary completion date changed from 17 Jan 2025 to 19 Dec 2025.